Niki BioSolutions Flags Substantial Doubt About Going Concern in First Post-Merger Financials

summarizeSummary

Niki BioSolutions disclosed a going concern warning in its first post-merger financials, citing substantial doubt about its ability to continue as a going concern within one year.

check_boxKey Events · Earnings and Guidance · NIKI

• Going Concern Warning

  Management determined that conditions raise substantial doubt about the Group's ability to continue as a going concern within one year after the date these financial statements are issued.

• Six-Month Financial Results

  Net loss of $1,307,300, negative working capital of $2,475,418, net operating cash outflow of $1,553,720, and accumulated deficit of $75,118,802 as of June 30, 2026.

• DiamiR Capital Shortfall

  DiamiR's standalone financial statements indicate its existing capital is not expected to be sufficient to fund operations for the next twelve months without additional financing.

• Warrant Liability Gain

  Recognized a non-cash gain of $164,000 from the change in fair value of warrant liability for the six months ended June 30, 2026.

auto_awesomeAnalysis · NIKI · Industrial Applications And Services

The company's first financial report after the DiamiR merger reveals a going concern warning. Management states substantial doubt about the company's ability to continue as a going concern within one year. The six-month results show a net loss of $1.3 million, negative working capital of $2.5 million, and cash burn of $1.6 million. DiamiR, the acquired entity, also lacks sufficient capital to fund operations for the next twelve months without additional financing. This is a critical disclosure for a micro-cap company with a market cap of only $7 million.